UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________
FORM 10-Q
(Mark One)
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 |
OR
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _________to_________
Commission File Number
000-19932
RELIV’ INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
Delaware | 371172197 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |
136 Chesterfield Industrial Boulevard, Chesterfield, Missouri | 63005 |
(Address of principal executive offices) | (Zip Code) |
(636) 537-9715
(Registrant’s telephone number, including area code)
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☑ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, par value $0.001 |
RELV |
NASDAQ Capital Market |
The number of shares outstanding of the Registrant’s common stock as of May 8, 2020 was 1,746,449 (excluding treasury shares).
INDEX
PART I -- FINANCIAL INFORMATION |
Item No. 1 - Financial Statements |
Reliv International, Inc. and Subsidiaries |
Condensed Consolidated Balance Sheets |
March 31 |
December 31 |
|||||||
2020 |
2019 |
|||||||
(unaudited) |
||||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 2,828,639 | $ | 1,630,779 | ||||
Accounts receivable, less allowances of $5,000 in 2020 and 2019 |
215,045 | 107,369 | ||||||
Notes & accounts receivables and deposits - related parties |
1,091,247 | 1,099,228 | ||||||
Inventories |
||||||||
Finished goods |
2,498,333 | 2,275,306 | ||||||
Raw materials |
208,666 | 305,571 | ||||||
Sales aids and promotional materials |
102,830 | 120,811 | ||||||
Total inventories |
2,809,829 | 2,701,688 | ||||||
Refundable income taxes |
245,503 | 22,406 | ||||||
Prepaid expenses and other current assets |
663,535 | 304,048 | ||||||
Total current assets |
7,853,798 | 5,865,518 | ||||||
Notes and accounts receivables - related parties |
2,390,930 | 2,418,921 | ||||||
Operating lease right-to-use assets |
265,936 | 354,440 | ||||||
Intangible assets, net |
1,665,782 | 1,722,277 | ||||||
Equity investment |
505,000 | 505,000 | ||||||
Property, plant and equipment: |
||||||||
Land and land improvements |
905,190 | 905,190 | ||||||
Building |
10,145,645 | 10,145,005 | ||||||
Office & other equipment |
1,230,768 | 1,237,142 | ||||||
Computer equipment & software |
2,197,639 | 2,240,063 | ||||||
14,479,242 | 14,527,400 | |||||||
Less: Accumulated depreciation |
10,119,806 | 10,086,560 | ||||||
Net property, plant and equipment |
4,359,436 | 4,440,840 | ||||||
Total assets |
$ | 17,040,882 | $ | 15,306,996 |
See notes to financial statements. |
Reliv International, Inc. and Subsidiaries |
Condensed Consolidated Balance Sheets |
March 31 |
December 31 |
|||||||
2020 |
2019 |
|||||||
(unaudited) |
||||||||
Liabilities and stockholders' equity |
||||||||
Current liabilities: |
||||||||
Accounts payable and accrued expenses: |
||||||||
Trade accounts payable and other accrued expenses |
$ | 2,155,345 | $ | 1,565,198 | ||||
Distributors' commissions payable |
1,210,104 | 891,492 | ||||||
Sales taxes payable |
267,909 | 139,542 | ||||||
Payroll and payroll taxes payable |
320,718 | 212,716 | ||||||
Total accounts payable and accrued expenses |
3,954,076 | 2,808,948 | ||||||
Income taxes payable |
161,113 | 121,177 | ||||||
Deferred revenue |
330,763 | 322,261 | ||||||
Operating lease liabilities |
178,463 | 236,771 | ||||||
Revolving line of credit |
500,000 | 500,000 | ||||||
Total current liabilities |
5,124,415 | 3,989,157 | ||||||
Noncurrent liabilities: |
||||||||
Operating lease liabilities |
76,648 | 103,580 | ||||||
Other noncurrent liabilities |
115,451 | 112,616 | ||||||
Total noncurrent liabilities |
192,099 | 216,196 | ||||||
Stockholders' equity: |
||||||||
Preferred stock, par value $.001 per share; 500,000 shares authorized; -0- shares issued and outstanding |
- | - | ||||||
Common stock, par value $.001 per share; 5,000,000 authorized; 2,110,013 shares issued and 1,746,449 shares outstanding |
2,110 | 2,110 | ||||||
Additional paid-in capital |
30,643,771 | 30,643,771 | ||||||
Accumulated deficit |
(12,093,159 | ) | (12,755,495 | ) | ||||
Accumulated other comprehensive loss: |
||||||||
Foreign currency translation adjustment |
(976,931 | ) | (937,320 | ) | ||||
Treasury stock |
(5,851,423 | ) | (5,851,423 | ) | ||||
Total stockholders' equity |
11,724,368 | 11,101,643 | ||||||
Total liabilities and stockholders' equity |
$ | 17,040,882 | $ | 15,306,996 |
See notes to financial statements. |
Reliv International, Inc. and Subsidiaries |
Condensed Consolidated Statements of Net |
Income and Comprehensive Income |
(unaudited) |
Three months ended March 31 |
|||||||
2020 |
2019 |
|||||||
Product sales |
$ | 9,548,817 | $ | 8,810,997 | ||||
Freight income |
558,095 | 519,941 | ||||||
Other revenue |
175,753 | 158,566 | ||||||
Net sales |
10,282,665 | 9,489,504 | ||||||
Costs and expenses: |
||||||||
Cost of goods sold |
2,654,843 | 2,433,732 | ||||||
Distributor royalties and commissions |
3,328,455 | 3,117,572 | ||||||
Selling, general and administrative |
3,777,682 | 3,739,527 | ||||||
Total costs and expenses |
9,760,980 | 9,290,831 | ||||||
Income from operations |
521,685 | 198,673 | ||||||
Other income (expense): |
||||||||
Interest income |
39,662 | 49,262 | ||||||
Interest expense |
(6,105 | ) | (5,412 | ) | ||||
Other income (expense) |
(70,906 | ) | (5,428 | ) | ||||
Gain on sale of fixed assets |
- | 434,549 | ||||||
Income before income taxes |
484,336 | 671,644 | ||||||
Provision (benefit) for income taxes |
(178,000 | ) | 48,000 | |||||
Net income |
$ | 662,336 | $ | 623,644 | ||||
Other comprehensive income (loss): |
||||||||
Foreign currency translation adjustment |
(39,611 | ) | 22,211 | |||||
Comprehensive income |
$ | 622,725 | $ | 645,855 | ||||
Earnings per common share - Basic & Diluted |
$ | 0.38 | $ | 0.36 | ||||
Weighted average shares |
1,746,000 | 1,746,000 |
See notes to financial statements. |
Reliv International, Inc. and Subsidiaries |
Condensed Consolidated Statements of Cash Flows |
(unaudited) |
Three months ended March 31 |
||||||||
2020 |
2019 |
|||||||
Operating activities: |
||||||||
Net income |
$ | 662,336 | $ | 623,644 | ||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |
||||||||
Depreciation and amortization |
143,789 | 144,893 | ||||||
Stock-based compensation |
- | 5,306 | ||||||
Non-cash other revenue |
- | (86,433 | ) | |||||
Non-cash miscellaneous loss |
- | 24,618 | ||||||
(Gain) loss on sale of property, plant and equipment |
- | (434,549 | ) | |||||
Foreign currency transaction (gain) loss |
87,162 | 5,925 | ||||||
(Increase) decrease in trade, accounts & notes receivable, and deposits from related parties |
(104,389 | ) | (839,989 | ) | ||||
(Increase) decrease in inventories |
(189,667 | ) | 705,371 | |||||
(Increase) decrease in refundable income taxes |
(223,097 | ) | 1,918 | |||||
(Increase) decrease in prepaid expenses and other current assets |
(364,638 | ) | (251,056 | ) | ||||
(Increase) decrease in other assets |
- | (49,681 | ) | |||||
Increase (decrease) in income taxes payable |
40,411 | 42,522 | ||||||
Increase (decrease) in accounts payable & accrued expenses, deferred revenue, and other noncurrent liabilities |
1,209,504 | (19,235 | ) | |||||
Net cash provided by (used in) operating activities |
1,261,411 | (126,746 | ) | |||||
Investing activities: |
||||||||
Purchase of property, plant and equipment |
(9,207 | ) | (38,890 | ) | ||||
Payments received on notes receivables - related parties |
31,928 | 49,691 | ||||||
Net cash provided by investing activities |
22,721 | 10,801 | ||||||
Financing activities: |
||||||||
Proceeds from line of credit borrowings |
- | 500,000 | ||||||
Net cash provided by financing activities |
- | 500,000 | ||||||
Effect of exchange rate changes on cash and cash equivalents |
(86,272 | ) | 7,058 | |||||
Increase (decrease) in cash and cash equivalents |
1,197,860 | 391,113 | ||||||
Cash and cash equivalents at beginning of period |
1,630,779 | 1,989,974 | ||||||
Cash and cash equivalents at end of period |
$ | 2,828,639 | $ | 2,381,087 | ||||
Supplementary disclosure of cash flow information: |
||||||||
Noncash investing & financing transactions (Note 3): |
See notes to financial statements. |
Reliv International, Inc. and Subsidiaries |
Condensed Consolidated Statements of |
Stockholders' Equity |
(unaudited) |
Accumulated |
||||||||||||||||||||||||||||||||
Additional |
Other |
|||||||||||||||||||||||||||||||
Common Stock |
Paid-In |
Accumulated |
Comprehensive |
Treasury Stock |
||||||||||||||||||||||||||||
Shares |
Amount |
Capital |
Deficit |
Loss |
Shares |
Amount |
Total |
|||||||||||||||||||||||||
Balance at December 31, 2019 |
2,110,013 | $ | 2,110 | $ | 30,643,771 | $ | (12,755,495 | ) | $ | (937,320 | ) | 363,564 | $ | (5,851,423 | ) | $ | 11,101,643 | |||||||||||||||
Net income |
- | - | - | 662,336 | - | - | - | 662,336 | ||||||||||||||||||||||||
Other comprehensive income (loss): |
||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
- | - | - | - | (39,611 | ) | - | - | (39,611 | ) | ||||||||||||||||||||||
Total comprehensive income |
622,725 | |||||||||||||||||||||||||||||||
Balance at March 31, 2020 |
2,110,013 | $ | 2,110 | $ | 30,643,771 | $ | (12,093,159 | ) | $ | (976,931 | ) | 363,564 | $ | (5,851,423 | ) | $ | 11,724,368 |
Accumulated |
||||||||||||||||||||||||||||||||
Additional |
Other |
|||||||||||||||||||||||||||||||
Common Stock |
Paid-In |
Accumulated |
Comprehensive |
Treasury Stock |
||||||||||||||||||||||||||||
Shares |
Amount |
Capital |
Deficit |
Loss |
Shares |
Amount |
Total |
|||||||||||||||||||||||||
Balance at December 31, 2018 |
2,110,013 | $ | 2,110 | $ | 30,622,547 | $ | (12,311,138 | ) | $ | (982,095 | ) | 264,853 | $ | (5,338,560 | ) | $ | 11,992,864 | |||||||||||||||
Net income |
- | - | - | 623,644 | - | - | - | 623,644 | ||||||||||||||||||||||||
Other comprehensive income (loss): |
||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
- | - | - | - | 22,211 | - | - | 22,211 | ||||||||||||||||||||||||
Total comprehensive income |
645,855 | |||||||||||||||||||||||||||||||
Treasury stock acquired (Note 2) |
- | - | - | - | - | 99,200 | (540,144 | ) | (540,144 | ) | ||||||||||||||||||||||
Other |
- | - | - | - | - | (489 | ) | 27,281 | 27,281 | |||||||||||||||||||||||
Stock-based compensation |
- | - | 5,306 | - | - | - | - | 5,306 | ||||||||||||||||||||||||
Balance at March 31, 2019 |
2,110,013 | $ | 2,110 | $ | 30,627,853 | $ | (11,687,494 | ) | $ | (959,884 | ) | 363,564 | $ | (5,851,423 | ) | $ | 12,131,162 |
See notes to financial statements. |
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
March 31, 2020
1. Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements and notes thereto have been prepared in accordance with the instructions to Form 10-Q and reflect all adjustments (which primarily include normal recurring accruals) which we believe are necessary to present fairly the financial position, results of operations and cash flows. All significant intercompany accounts and transactions have been eliminated. These statements, however, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States. Interim results may not necessarily be indicative of results that may be expected for any other interim period or for the year as a whole. These financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the annual report on Form 10-K for the year ended December 31, 2019, filed March 27, 2020 with the Securities and Exchange Commission.
Impact of COVID-19 Pandemic
In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic, which continues to spread throughout the U.S. and the world and has resulted in government authorities implementing numerous measures to contain the virus, including travel bans and restrictions, quarantines, shelter-in-place orders, and business limitations and shutdowns. While we are unable to accurately predict the full impact that COVID-19 will have on our results from operations, financial condition, liquidity and cash flows due to numerous uncertainties, including the duration and severity of the pandemic and containment measures, our compliance with these measures has impacted our day-to-day operations and could disrupt our business and operations, as well as that of our distributors, customers, suppliers (including contract manufacturers) and other counterparties, for an indefinite period of time. To support the health and well-being of our employees, customers, partners and communities, a vast majority of our employees have been working remotely since March 2020.
The ultimate impact of the COVID-19 pandemic on our worldwide operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments may direct resulting in an extended period of continued business disruption and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material adverse impact on our business, financial condition and results of operations.
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
1. Accounting Policies (continued)
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require updates to our estimates or judgments or require us to revise the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under unanticipated conditions or assumptions.
Concentrations of Risk
Effective January 1, 2019, we have entered into outsourcing agreements with Nutracom LLC (“Nutracom”) to manufacture our nutritional and dietary supplements and for warehousing and fulfillment services for the U.S. distribution of our products. Nutracom has also issued promissory notes to us for the acquisition of our manufacturing and fulfillment operations. Any inability of Nutracom to deliver these contracted services or to repay the promissory notes could adversely impact our future operating results and valuation of our Nutracom equity investment. See Note 2 and Note 3 for further discussion of our relationship with Nutracom.
Variable Interest Entities (VIE) - Unconsolidated
Effective January 1, 2019, we have a financial interest in Nutracom. If we are the primary beneficiary of a VIE, we are required to consolidate the VIE in our consolidated financial statements. To determine if we are the primary beneficiary, we evaluate whether we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Our VIE evaluation requires significant assumptions and judgments.
We do not have the power to direct the significant activities of Nutracom, primarily because we do not have governance rights. We also do not participate in the annual profits or losses of Nutracom. Therefore, we do not consolidate the financial results of Nutracom in our consolidated financial statements. We account for our financial interest in Nutracom as an equity investment measured at cost minus impairment, if any. A cost method equity investment is subject to periodic impairment review using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and our ability and intent to hold the investment for a sufficient period of time to allow for recovery.
See Note 2 and Note 3 for further information on our financial relationship with Nutracom.
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
1. Accounting Policies (continued)
New Accounting Pronouncements – Not Yet Adopted
In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updated (“ASU”) No. 2016-13, Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments which requires entities to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology may result in earlier recognition of losses than under the current incurred loss approach, which requires waiting to recognize a loss until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial assets may be recorded and presented, and that expand disclosures. This standard will be effective for our interim and annual financial periods beginning January 1, 2023, with early adoption permitted. Adoption of this standard must be applied on a modified retrospective basis. We are evaluating the potential impact of this standard on our consolidated financial statements and related disclosures.
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which adds new guidance for accounting for tax law changes, year-to-date losses in interim periods, and certain franchise-type taxes, as well as other changes to simplify accounting for income taxes. This standard will be effective for our interim and annual financial periods beginning January 1, 2021, with early adoption permitted. The adoption methodologies for this standard vary; subject to the specific provision(s) within the standard being adopted. We are evaluating the potential impact of this standard on our consolidated financial statements and related disclosures.
Going Concern
We have incurred operating losses, declining net sales, and negative net cash flows over our most recent five years. Our management estimates that these unfavorable trends are more likely than not to continue for the foreseeable future, and as a result, we will require additional financial support to fund our operations and execute our business plan. As of March 31, 2020, we had $2,828,639 in cash and cash equivalents which may not be sufficient to fund our planned operations through one year subsequent to the date of the issuance of these condensed financial statements, and accordingly, there is substantial doubt about our ability to continue as a going concern.
In the event that we do not generate sufficient liquidity from operations and should we be unable to obtain sufficient additional capital or borrowings, we may have to engage in any or all of the following activities: (i) seek to monetize our headquarters building via traditional bank lending or a sale and leaseback-type transaction; (ii) monetizing the note receivable from a distributor; (iii) modify our distributor promotions, incentives, and other activities; (iv) cease operations in certain geographic regions, and (v) reduce employee compensation and benefits.
These actions may have a material adverse impact on our ability to achieve certain of our planned objectives. Even if we are able to source additional funding, we may be forced to significantly reduce our operations or shut down our operations if our business operating performance does not improve. These condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event we can no longer continue as a going concern.
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
2. Sale of Manufacturing Operations’ Assets
On January 1, 2019, we entered into a Purchase Agreement with Nutracom pursuant to which Nutracom purchased the following assets previously used by us in our manufacturing operations:
● |
Inventories (sold at cost of $1.56 million) and, |
● |
Machinery and other equipment with a net book value of $565,000 (sold for $1 million; gain on disposal of approximately $435,000). |
Nutracom was formed by our manufacturing operations management which included former officers of the Company. Employees of our manufacturing operations were offered employment by Nutracom.
Prior to its approval of the transaction, our Board of Directors formed a special committee consisting of the Board’s independent directors to review the transaction. To assist in its review, the special committee engaged a qualified third-party expert to render a fairness opinion on the transaction.
Concurrently with the execution of the Purchase Agreement, we entered into several agreements with Nutracom including a product supply agreement for a term of seven years, a fulfillment agreement, and a facility lease agreement whereby Nutracom will lease manufacturing, warehouse, and certain office space of our headquarters building from us for a term of seven years, with a Nutracom option for an additional five-year term. Annual lease amounts range from $193,000 to $410,000 over the seven-year term.
Nutracom provided the following consideration to us for the manufacturing operations and related identified assets and agreements:
● |
$1 million secured promissory note, seven year term, fixed interest rate of 5.5%, principal and interest payable monthly. (See June 1, 2019 note modification within this Note 2). |
● |
$764,344 unsecured promissory note, seven year term, fixed interest rate of 7.0%, interest only payable for the first two years with monthly payment of principal and interest thereafter under a ten-year amortization schedule. The face value of the unsecured note includes the first year’s rent due under the facility lease agreement. (See October 1, 2019 note modification within this Note 2). |
● |
Nutracom management transferred to us its ownership of 99,200 shares of our common stock valued at $540,144. |
● |
Nutracom issued to us a non-voting Class B 15% equity membership interest in Nutracom, LLC. The Class B interest does not share in any profits or losses from operations of Nutracom. As defined within the Nutracom Operating Agreement, upon any merger, consolidation, disposition, or liquidation of Nutracom, the Class B equity membership interest converts to a Class A equity membership interest. |
● |
Commencing January 1, 2020, our Class B interest is entitled to receive a percentage, (ranging from 1.0% to 1.25%) of Nutracom’s annual revenues (excluding Nutracom’s revenues from sales to us). |
Our non-voting Class B 15% equity membership interest in Nutracom was valued by the aforementioned third-party expert at $505,000. As our non-voting membership interest does not participate in the management of Nutracom, nor do we share in any Nutracom operating profits or losses, we are accounting for our Nutracom equity investment under the cost method.
We accounted for the aforementioned Nutracom transactions in our first quarter 2019 financial results.
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
2. Sale of Manufacturing Operations’ Assets (continued)
Promissory Note Modification – June 1, 2019
On June 1, 2019, we entered into an Agreement with Nutracom to modify the Secured Promissory Note originally issued to us by Nutracom on January 1, 2019, as follows:
● |
Effective June 1, 2019, the outstanding balance of the Secured Promissory Note was reduced by $500,000 to $460,583 with a corresponding reduction of $500,000 to our outstanding vendor obligation due Nutracom under our ongoing product supply agreement. |
● |
The $460,583 remaining Secured Promissory Note was exchanged with Nutracom for a newly issued June 1, 2019 Nutracom unsecured promissory note for the same amount under the following terms: fixed interest rate of 6.0% with interest only payable monthly through December 2020. Beginning January 1, 2021, principal and interest of $8,904 will be payable monthly for 60 months. |
Promissory Note Modification – October 1, 2019
In December 2019, we entered into an Agreement with Nutracom to modify the Unsecured Promissory Note originally issued to us by Nutracom on January 1, 2019, as follows:
● |
Effective October 1, 2019, the outstanding balance of the January 1, 2019 Unsecured Promissory Note of $764,344 was reduced to $711,163. The reduction of $53,181 in the Note’s balance represents Nutracom’s return to us of now-expired inventories originally acquired by Nutracom from us on January 1, 2019. |
● |
The $711,163 remaining balance of the January 1, 2019 Unsecured Promissory Note was exchanged with Nutracom for a newly issued October 1, 2019 Nutracom Unsecured Promissory Note for the same amount under the following terms: fixed interest rate of 7.0% with interest only payable monthly through December 2020. Beginning January 1, 2021, principal and interest of $8,257, under a ten-year amortization schedule, will be payable monthly for 60 months, with a balloon payment of all remaining principal and interest due January 1, 2026. |
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
3. Related Parties
The following summarizes our related party activities with Nutracom and a significant distributor of the Company.
March 31 |
December 31 |
|||||||
Assets and liabilities - related parties |
2020 |
2019 |
||||||
Notes & accounts receivables and deposits - current |
||||||||
Deposits with Nutracom for inventory |
$ | 887,887 | $ | 941,154 | ||||
Note receivable - distributor |
132,598 | 130,629 | ||||||
Note receivable - Nutracom unsecured DTD 6/1/2019 |
19,904 | - | ||||||
Note receivable - Nutracom unsecured DTD 10/1/2019 |
12,398 | - | ||||||
Other miscellaneous receivables |
38,460 | 27,445 | ||||||
$ | 1,091,247 | $ | 1,099,228 | |||||
Notes & accounts receivables - non-current |
||||||||
Note receivable - distributor |
$ | 1,117,546 | $ | 1,151,443 | ||||
Note receivable - Nutracom unsecured DTD 6/1/2019 |
440,679 | 460,583 | ||||||
Note receivable - Nutracom unsecured DTD 10/1/2019 |
698,765 | 711,163 | ||||||
Unbilled receivables: Straight line rent revenue greater than rental billings |
133,940 | 95,732 | ||||||
$ | 2,390,930 | $ | 2,418,921 | |||||
Equity investment in Nutracom |
$ | 505,000 | $ | 505,000 | ||||
Liability captions with Nutracom balances included therein |
||||||||
Trade accounts payable and other accrued expenses |
$ | 459,978 | $ | 430,907 |
The following table presents scheduled principal payments to be received on the distributor and Nutracom promissory notes receivable:
Remainder of 2020 |
$ | 98,701 | ||
2021 |
271,037 | |||
2022 |
288,294 | |||
2023 |
306,655 | |||
2024 |
326,190 | |||
Thereafter |
1,131,013 | |||
$ | 2,421,890 |
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
3. Related Parties (continued)
Three months ended March 31 |
||||||||
Revenue and expense - related parties |
2020 |
2019 |
||||||
Other revenue |
$ | 175,753 | $ | 158,566 | ||||
Selling, general and administrative expense: |
||||||||
Fullfillment & professional fees |
159,984 | 151,102 | ||||||
Interest income on promissory notes |
38,346 | 47,843 | ||||||
Royalty income (other income/expense) |
13,872 | - | ||||||
Gain on sale of fixed assets |
- | 434,549 | ||||||
Finished goods inventory purchased from Nutracom |
$ | 2,036,600 | $ | 979,900 |
At March 31, 2020, we had $1.01 million in commitments (net of deposits) to purchase finished goods inventory from Nutracom.
Supplementary Disclosure of Cash Flows Information:
We incurred the following noncash investing and financing transactions on January 1, 2019 relating to our transactions with Nutracom:
2019 |
||||
January 1, 2019 |
||||
Sale of fixed assets |
$ | 1,000,000 | ||
Sale of inventories |
1,559,488 | |||
First year building rental received in advance |
250,000 | |||
Acquire company common stock for treasury |
540,144 | |||
Acquire equity investment in Nutracom |
505,000 | |||
Secured promissory note received |
1,000,000 | |||
Unsecured promissory note received |
764,344 |
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
4. Fair Value of Financial Instruments
Fair value can be measured using valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). Accounting standards utilize a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those levels:
Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets or similar assets or liabilities in markets that are not active.
Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
The carrying amount and fair value of financial instruments were approximately as follows:
Revolving line of credit: The fair value of our revolver loan approximates carrying value as this loan was amended within the past year and has a variable market-based interest rate that resets every thirty days. (Fair value is only disclosed).
Note receivable - distributor: The note receivable - distributor is a variable rate residential mortgage-based financial instrument. An average of published interest rate quotes for a fifteen-year residential jumbo mortgage, a comparable financial instrument, was used to estimate fair value of this note receivable under a discounted cash flow model. (Fair value is only disclosed)
Notes receivable - Nutracom: The notes receivable - Nutracom represent two fixed rate promissory notes issued by a privately-held entity (PHE). We developed an estimated market discount rate based upon the PHE’s third party incremental variable borrowing rate plus a risk-adjustment factor to estimate the fair value of these notes receivable under a discounted cash flow model. (Fair value is only disclosed).
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
4. Fair Value of Financial Instruments (continued)
The carrying value of other financial instruments, including cash, accounts receivable and accounts payable, and accrued liabilities approximate fair value due to their short maturities or variable-rate nature of the respective balances.
5. Debt
On September 30, 2015, we entered into a series of lending agreements with our primary lender which included agreements for a term loan and a revolving credit facility. The term loan was repaid in 2018 and the revolver has been periodically amended and extended.
Effective with a September 11, 2018 amendment, the revolving line of credit’s maximum borrowing amount was $750,000. The revolver’s maturity date was April 29, 2019 and the revolver’s interest rate was based on the 30-day LIBOR plus 2.25%. In January 2019, we borrowed $500,000 under the revolving line of credit.
Effective with a March 25, 2019 amendment, the revolving line of credit’s maturity date was extended to April 28, 2020 and the interest rate was revised to the 30-day LIBOR plus 3.00%. As amended, the revolver’s maximum borrowing amount remains $750,000. At March 31, 2020, outstanding borrowings under the revolving line of credit were $500,000 at an interest rate of 4.36%.
On April 28, 2020, our revolving line of credit agreement was extended six months to October 28, 2020 under the same terms and conditions as the expiring agreement.
Borrowings under the lending agreement continue to be secured by all of our tangible and intangible assets and by a mortgage on the real estate of our headquarters facility. At March 31, 2020, we were in compliance with our loan covenant requirements.
6. Income Taxes
During the fiscal years of 2016 through 2019, we determined that it was more likely than not losses generated in the U.S. and certain foreign jurisdictions will not be realized based on projections of future taxable income, estimated reversals of existing taxable timing differences, and other considerations. In prior years, we recorded a valuation allowance on all of our domestic and foreign deferred tax assets.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act became effective in the U.S. Under the CARES Act, U.S. Net Operating Losses (NOLs) arising in our calendar tax years 2018, 2019, and 2020 may be carried back to each of the five tax years preceding the tax year of such loss. Based on this new legislation, at March 31, 2020, we have recorded a $225,000 estimated income tax benefit for NOL carryback.
The effective income tax rate was (36.8)% and 7.1% for the year to date periods ended March 31, 2020 and 2019, respectively. In addition to the CARES Act tax benefit previously described, for each year to date period, the income tax provision amounts include estimated income taxes for one of the Company’s foreign subsidiaries and certain U.S. states.
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
6. Income Taxes (continued)
Tax Audits
One of our foreign subsidiaries had been under local country audit for greater than ten years for alleged deficiencies in various tax types for the years 2004 through 2006. We settled the 2005 and 2006 tax year audits in November 2019. In December 2019, we had an agreement in principle with the local tax authority to settle the tax year 2004 audit. At December 31, 2019, we had an estimated full reserve of approximately $84,000 for resolution of this matter; with such amount remitted to the tax authority in February 2020.
During the third quarter of 2019, the U.S. Internal Revenue Service (IRS) commenced an examination of our 2017 U.S. federal income tax return.
7. Revenue Recognition
We recognize revenue from product sales under a five step process with our independent distributors (including customers) when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Product sales revenue (principally nutritional and dietary supplements) and commission expenses are recorded when control is transferred to the independent distributors, which occurs at the time of shipment. Generally, net sales reflect product sales less the distributor discount of 20 percent to 40 percent of the suggested retail price. We present distributor royalty and commission expense as an operating expense, rather than a reduction to net sales, as these payments are not made to the purchasing distributor. At point of sale, we receive payment by credit card, personal check, or guaranteed funds for contracts from independent distributors and make related commission payments in the following month.
We recognize the performance obligation for membership fees-type revenue over the membership term of generally twelve months. We receive payment for membership fees revenue at the beginning of the membership term and recognize membership fees revenue on a straight-line basis in correlation with the completion of our performance obligation under the membership term. Our remaining unearned membership fees obligation is reported as deferred revenue liability.
We record freight income as a component of net sales and record freight costs as a component of cost of goods sold. Total sales do not include sales tax as we consider ourselves a pass-through conduit for collecting and remitting applicable sales taxes.
Other revenue is defined in Note 8 – Lease Revenue.
Actual and estimated sales returns are classified as a reduction of net sales. We estimate and accrue a reserve for product returns based on our return policy and historical experience. Our product returns policy allows for distributors to return product only upon termination of his or her distributorship. Allowable returns are limited to saleable product which was purchased within twelve months of the termination for a refund of 100% of the original purchase price less any distributor royalties and commissions received relating to the original purchase of the returned products. For the year to date periods ending March 31, 2020 and 2019, total returns as a percent of net sales were each 0.04%, respectively.
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
7. Revenue Recognition (continued)
We classify our net sales into three categories of sales products, plus freight income, and other revenue:
Three months ended |
||||||||
March 31 |
||||||||
2020 |
2019 |
|||||||
Net sales by product category |
||||||||
Nutritional and dietary supplements |
$ | 8,843,151 | $ | 8,497,350 | ||||
Other supplements |
417,229 | - | ||||||
Sales aids, membership fees, and other |
288,437 | 313,647 | ||||||
Freight income |
558,095 | 519,941 | ||||||
Other revenue |
175,753 | 158,566 | ||||||
Total net sales |
$ | 10,282,665 | $ | 9,489,504 |
We operate in one reportable segment, a network marketing segment consisting of six operating units that sell nutritional and dietary products to a sales force of independent distributors that sell the products directly to customers. These operating units are based on geographic regions, as follows:
Three months ended |
||||||||
March 31 |
||||||||
2020 |
2019 |
|||||||
Net sales by geographic region |
||||||||
United States |
$ | 7,842,435 | $ | 7,111,773 | ||||
Australia/New Zealand |
170,122 | 177,048 | ||||||
Canada |
158,661 | 199,399 | ||||||
Mexico |
128,621 | 136,026 | ||||||
Europe (1) |
962,092 | 938,668 | ||||||
Asia (2) |
1,020,734 | 926,590 | ||||||
Total net sales |
$ | 10,282,665 | $ | 9,489,504 |
(1) |
Europe consists of United Kingdom, Ireland, France, Germany, Austria, and the Netherlands. |
|
(2) |
Asia consists of Philippines and Malaysia. |
8. Lease Revenue
Other revenue consists of revenue derived from leasing a portion of our headquarters building to Nutracom effective January 1, 2019. The leased space, encompassing manufacturing, warehouse, and certain office space, is for a term of seven years, with a tenant option for an additional five-year term. Annual lease amounts range from $193,000 to $410,000 over the seven-year term.
We recognize lessor rent revenue on a straight-line basis over the term of the lease. As part of this straight-line methodology, the cumulative rental billings may be greater or less than the financial period’s recognized revenue; such timing differences are recognized on the balance sheet as an accrued other liability or an unbilled rent revenue receivable.
Reliv’ International, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(Unaudited)
8. Lease Revenue (continued)
Also included in other revenue are billings to the tenant for its share of the facility’s common area costs such as real estate taxes, maintenance, and utilities; totaling approximately $89,000 and $72,000 for the three month periods ending March 31, 2020 and 2019, respectively. These same common area costs plus the tenant’s share of the facilities’ depreciation are recorded as cost of goods sold.
The following table details lessor’s estimated remaining straight-line rent revenue over the seven-year lease term as compared with fixed rent amounts under the lease agreement.
Estimated |
||||||||
Straight-line |
Lease Agreement |
|||||||
Rent Revenue |
Fixed Rent |
|||||||
Remainder of 2020 |
$ | 259,299 | $ | 144,675 | ||||
2021 |
345,732 | 385,800 | ||||||
2022 |
345,732 | 385,800 | ||||||
2023 |
345,732 | 385,800 | ||||||
2024 |
345,732 | 409,913 | ||||||
Thereafter |
345,733 | 409,912 | ||||||
Total |
$ | 1,987,960 | $ | 2,121,900 |
9. Subsequent Events
As described in Note 5, on April 28, 2020, our revolving line of credit agreement with our primary lender was extended six months to October 28, 2020.
On May 4, 2020, we executed a promissory note (“SBA Note”) dated April 20, 2020 in the amount of $862,000 with our primary lender under the recently enacted CARES Act Payroll Protection Program (“PPP”). In accordance with the PPP, we will use the loan proceeds of $862,000 primarily for payroll costs. The PPP SBA Note is scheduled to mature April 20, 2022 and has an interest rate of 1.0%. The PPP SBA Note is subject to the terms and conditions applicable to loans administered by the U.S. Small Business Administration under the CARES Act.
FORWARD-LOOKING STATEMENTS
This quarterly report includes both historical and “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future results. Words such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this quarterly report on Form 10-Q. We disclaim any intent or obligation to update any forward-looking statements after the date of this quarterly report to conform such statements to actual results or to changes in our opinions or expectations.
Item No. 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis discusses the financial condition and results of our operations on a consolidated basis, unless otherwise indicated.
Overview
We are a developer and marketer of a proprietary line of nutritional supplements addressing basic nutrition, specific wellness needs, weight management and sports nutrition. In 2019, we introduced a line of hemp-extract products under the RLV brand name. We sell our products through an international direct selling system utilizing independent distributors. Sales in the United States represented approximately 76.3% of worldwide net sales for the three months ended March 31, 2020 compared to approximately 74.9% for the three months ended March 31, 2019. Our international operations currently generate sales through distributor networks with facilities in Australia, Canada, Malaysia, Mexico, the Philippines, and the United Kingdom. We also operate in Ireland, France, Germany, Austria and the Netherlands from our United Kingdom distribution center, and in New Zealand from our Australia office.
We derive our revenues principally through product sales made by our global independent distributor base, which, as of March 31, 2020, consisted of approximately 13,680 registered customers and 25,550 active distributors. Our sales can be affected by several factors, including our ability to attract new distributors and retain our existing distributor base, our ability to properly train and motivate our distributor base and our ability to develop new products and successfully maintain our current product line.
All of our sales to distributors outside the United States are made in the respective local currency; therefore, our earnings and cash flows are subject to fluctuations due to changes in foreign currency rates as compared to the U.S. dollar. Our foreign subsidiaries primarily source their nutritional and dietary inventories in U.S. dollars from our U.S. manufacturer. As a result, exchange rate fluctuations may have an effect on sales and gross margins. Accounting practices require that our results from operations be converted to U.S. dollars for reporting purposes. Consequently, our reported earnings may be significantly affected by fluctuations in currency exchange rates, generally increasing with a weaker U.S. dollar and decreasing with a strengthening U.S. dollar. From time to time, we enter into foreign exchange forward contracts to mitigate our foreign currency exchange risk.
Impact of COVID-19 Pandemic
In March 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic, which continues to spread throughout the U.S. and the world and has resulted in government authorities implementing numerous measures to contain the virus, including travel bans and restrictions, quarantines, shelter-in-place orders, and business limitations and shutdowns. While we are unable to accurately predict the full impact that COVID-19 will have on our results from operations, financial condition, liquidity and cash flows due to numerous uncertainties, including the duration and severity of the pandemic and containment measures, our compliance with these measures has impacted our day-to-day operations and could disrupt our business and operations, as well as that of our distributors, customers, suppliers (including contract manufacturers) and other counterparties, for an indefinite period of time. To support the health and well-being of our employees, customers, partners and communities, a vast majority of our employees have been working remotely since March 2020.
The ultimate impact of the COVID-19 pandemic on our worldwide operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments may direct resulting in an extended period of continued business disruption and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material adverse impact on our business, financial condition and results of operations.
Components of Net Sales and Expense
Product sales represent the actual product purchase price typically paid by our distributors, after giving effect to distributor allowances, which can range from 20% to 40% of suggested retail price, depending on the rank of a particular distributor. Freight income represents the amounts billed to distributors for shipping costs. We record net sales and the related commission expense when the merchandise is shipped. Other revenue included in net sales includes the leasing revenue, plus common area expense billings, on the lease of the manufacturing portion of our building to Nutracom, LLC (“Nutracom”) as of January 1, 2019.
Our primary expenses include cost of products sold, distributor royalties and commissions and selling, general and administrative expenses.
Our cost of goods sold consists of the purchase price of the products, along with shipping costs, and duties and taxes where applicable. Cost of goods sold also include the costs related to leasing income.
Distributor royalties and commissions are monthly payments made to distributors based on products sold in their downline organization. Based on our distributor agreements, these expenses have typically approximated 23% of sales at suggested retail. Wholesale pricing discounts on distributor orders are based on the retail value of the product. Distributor royalties and commissions are paid on an amount referred to as the business value (“BV”), which typically ranges between 80% and 90% of the suggested retail price of each product. Also, we include other sales leadership bonuses, such as Ambassador bonuses, within this caption. Overall, distributor royalties and commissions remain directly related to the level of our sales and should continue at comparable levels as a percentage of net sales going forward.
Selling, general and administrative expenses include the compensation and benefits paid to our employees, all other selling expenses, marketing, promotional expenses, travel and other corporate administrative expenses. These other corporate administrative expenses include professional fees, depreciation and amortization, occupancy costs, communication costs and other similar operating expenses. Selling, general and administrative expenses can be affected by a number of factors, including staffing levels and the cost of providing competitive salaries and benefits; the amount we decide to invest in distributor training and motivational initiatives; and the cost of regulatory compliance.
Results of Operations
Net Sales. Overall net sales increased by 8.4% in the three months ended March 31, 2020 compared to the same period in 2019. During the first quarter of 2020 (“Q1 2020”), sales in the United States increased by 10.3% and international sales increased by 2.6% over the prior-year period. International sales, when reported in U.S. dollars, were negatively impacted in the aggregate by a stronger U.S. dollar versus most of the currencies in which we conduct business. Excluding the impact of currency exchange fluctuation, international sales increased by 2.9%.
The following table summarizes net sales by geographic market for the three months ended March 31, 2020 and 2019.
Three months ended March 31, |
||||||||||||||||||||||||
2020 |
2019 |
Change from prior year |
||||||||||||||||||||||
Amount |
% of Net Sales |
Amount |
% of Net Sales |
Amount |
% |
|||||||||||||||||||
(dollars in thousands) |
||||||||||||||||||||||||
United States |
$ | 7,842 | 76.3 |
% |
$ | 7,112 | 74.9 |
% |
$ | 730 | 10.3 |
% |
||||||||||||
Australia/New Zealand |
170 | 1.6 | 177 | 1.9 | (7 |
) |
(4.0 |
) |
||||||||||||||||
Canada |
159 | 1.5 | 199 | 2.1 | (40 |
) |
(20.1 |
) |
||||||||||||||||
Mexico |
129 | 1.3 | 136 | 1.4 | (7 |
) |
(5.1 |
) |
||||||||||||||||
Europe |
962 | 9.4 | 939 | 9.9 | 23 | 2.4 | ||||||||||||||||||
Asia |
1,021 | 9.9 | 927 | 9.8 | 94 | 10.1 | ||||||||||||||||||
Consolidated total |
$ | 10,283 | 100.0 |
% |
$ | 9,490 | 100.0 |
% |
$ | 793 | 8.4 |
% |
The following tables set forth, as of March 31, 2020 and 2019, the number of our Retail Customers/ Preferred Customers/Active Distributors and Master Affiliates and above. The total number of active distributors includes Master Affiliates and above. We define an active retail or preferred customer as one that has placed a product order in the prior twelve months, and we define an active distributor as one that enrolls as a distributor or renews his or her distributorship during the prior twelve months. Many individuals join Reliv as distributors to obtain our products at a discount and may not participate in the Reliv business opportunity. Master Affiliates and above are distributors that have attained the highest level of discount and are eligible for royalties generated by Master Affiliate groups in their downline organization.
Retail and Preferred Customers/Active Distributors/Master Affiliates and Above by Market |
As of 3/31/2020 |
||||||||||||||||||||
Retail Customers |
Preferred Customers |
Active Distributors |
Total Customers and Distributors |
Master Affiliates and Above |
||||||||||||||||
United States |
3,580 | 1,450 | 17,460 | 22,490 | 1,860 | |||||||||||||||
Australia/New Zealand |
50 | 210 | 650 | 910 | 80 | |||||||||||||||
Canada |
80 | 30 | 470 | 580 | 60 | |||||||||||||||
Mexico |
20 | 100 | 1,050 | 1,170 | 80 | |||||||||||||||
Europe |
690 | 660 | 1,620 | 2,970 | 260 | |||||||||||||||
Asia |
1,370 | 5,440 | 4,300 | 11,110 | 610 | |||||||||||||||
Consolidated Total |
5,790 | 7,890 | 25,550 | 39,230 | 2,950 |
As of 3/31/2019 |
||||||||||||||||||||
Retail Customers |
Preferred Customers |
Active Distributors |
Total Customers and Distributors |
Master Affiliates and Above |
||||||||||||||||
United States |
3,960 | 1,560 | 18,040 | 23,560 | 1,880 | |||||||||||||||
Australia/New Zealand |
40 | 220 | 710 | 970 | 70 | |||||||||||||||
Canada |
100 | 20 | 520 | 640 | 60 | |||||||||||||||
Mexico |
10 | 110 | 1,020 | 1,140 | 80 | |||||||||||||||
Europe |
560 | 1,140 | 1,800 | 3,500 | 300 | |||||||||||||||
Asia |
3,020 | 3,950 | 3,210 | 10,180 | 350 | |||||||||||||||
Consolidated Total |
7,690 | 7,000 | 25,300 | 39,990 | 2,740 |
Change in % |
||||||||||||||||||||
Retail Customers |
Preferred Customers |
Active Distributors |
Total Customers and Distributors |
Master Affiliates and Above |
||||||||||||||||
United States |
-9.6 | % | -7.1 | % | -3.2 | % | -4.5 | % | -1.1 | % | ||||||||||
Australia/New Zealand |
25.0 | % | -4.5 | % | -8.5 | % | -6.2 | % | 14.3 | % | ||||||||||
Canada |
-20.0 | % | 50.0 | % | -9.6 | % | -9.4 | % | 0.0 | % | ||||||||||
Mexico |
100.0 | % | -9.1 | % | 2.9 | % | 2.6 | % | 0.0 | % | ||||||||||
Europe |
23.2 | % | -42.1 | % | -10.0 | % | -15.1 | % | -13.3 | % | ||||||||||
Asia |
-54.6 | % | 37.7 | % | 34.0 | % | 9.1 | % | 74.3 | % | ||||||||||
Consolidated Total |
-24.7 | % | 12.7 | % | 1.0 | % | -1.9 | % | 7.7 | % |
The following table provides key statistics related to customer and distributor activity by market and should be read in conjunction with the following discussion.
Distributor Activity by Market |
International |
|||||||||||||||||||||||||||
United States |
AUS/NZ |
Canada |
Mexico |
Europe |
Asia |
-- Total |
||||||||||||||||||||||
Sales in USD (in 000's): |
||||||||||||||||||||||||||||
Quarter ended 3/31/2020 |
$ | 7,842 | $ | 170 | $ | 159 | $ | 129 | $ | 962 | $ | 1,021 | $ | 2,441 | ||||||||||||||
Quarter ended 3/31/2019 |
$ | 7,112 | $ | 177 | $ | 199 | $ | 136 | $ | 939 | $ | 927 | $ | 2,378 | ||||||||||||||
% change in sales-Q1 2020 vs. Q1 2019: |
||||||||||||||||||||||||||||
in USD |
10.3 | % | -4.0 | % | -20.1 | % | -5.1 | % | 2.4 | % | 10.1 | % | 2.6 | % | ||||||||||||||
due to currency fluctuation |
- | -7.7 | % | -0.4 | % | -2.8 | % | -1.8 | % | 3.0 | % | -0.3 | % | |||||||||||||||
Sales in local currency (non-GAAP) |
10.3 | % | 3.7 | % | -19.7 | % | -2.3 | % | 4.2 | % | 7.1 | % | 2.9 | % | ||||||||||||||
# of new Preferred Customers-Q1 2020 |
288 | 12 | 3 | 15 | 87 | 409 | 526 | |||||||||||||||||||||
# of new Preferred Customers-Q1 2019 |
329 | 17 | 6 | 12 | 144 | 1,987 | 2,166 | |||||||||||||||||||||
% change |
-12.5 | % | -29.4 | % | -50.0 | % | 25.0 | % | -39.6 | % | -79.4 | % | -75.7 | % | ||||||||||||||
# of new distributors-Q1 2020 |
694 | 10 | 13 | 99 | 127 | 495 | 744 | |||||||||||||||||||||
# of new distributors-Q1 2019 |
573 | 11 | 6 | 239 | 117 | 508 | 881 | |||||||||||||||||||||
% change |
21.1 | % | -9.1 | % | 116.7 | % | -58.6 | % | 8.5 | % | -2.6 | % | -15.6 | % | ||||||||||||||
# of new Master Affiliates-Q1 2020 |
175 | 9 | 10 | 3 | 22 | 99 | 143 | |||||||||||||||||||||
# of new Master Affiliates-Q1 2019 |
140 | 1 | 0 | 8 | 19 | 99 | 127 | |||||||||||||||||||||
% change |
25.0 | % | 800.0 | % | --- | -62.5 | % | 15.8 | % | 0.0 | % | 12.6 | % | |||||||||||||||
# of Product orders-Q1 2020 |
27,467 | 994 | 548 | 966 | 3,119 | 8,532 | 14,159 | |||||||||||||||||||||
# of Product orders-Q1 2019 |
25,758 | 975 | 558 | 975 | 3,031 | 10,663 | 16,202 | |||||||||||||||||||||
% change |
6.6 | % | 1.9 | % | -1.8 | % | -0.9 | % | 2.9 | % | -20.0 | % | -12.6 | % |
Use of Non-GAAP Financial Information
Net sales expressed in local currency or net sales adjusted for the impact of foreign currency fluctuation are non-GAAP financial measures. We use these measurements to assess the level of business activity in a foreign market, absent the impact of foreign currency fluctuation relative to the U.S. dollar, which our local management has no ability to influence. This is a meaningful measurement to management, and we believe this is a useful measurement to provide to shareholders.
United States
● |
Net sales in the United States increased by 10.3% in Q1 2020 compared to the prior-year quarter. Most measurements of distributor activity increased in Q1 2020 compared to the prior-year quarter. Sales activity, particularly in March, was driven by strong consumer demand for our products in the early stages of the COVID-19 pandemic, as shown by a 6.6% increase in product orders in Q1 2020. |
● |
Products in the LunaRich line, including Reliv Now® and LunaRich X™, continued to perform well, constituting 14.5% and 11.1% of net sales in the United States, respectively, in Q1 2020. Reliv NOW and LunaRich X represented 15.1% and 12.8%, respectively, of net sales in the United States in the prior-year quarter. |
● |
Sales of our RLV line of hemp-extract products, introduced in June 2019, represented 6.6% of net sales in the United States in Q1 2020. Initially, the RLV line included three liquid tinctures and one balm, and a new sleep-aid tincture with melatonin was introduced in Q1 2020. All of the RLV products are derived from organically-grown, non-GMO hemp. The RLV line represented 4.9% of net sales in United States in 2019. |
● |
New distributor enrollments and new Master Affiliate qualifications increased by 21.1% and 25.0%, respectively, in Q1 2020 compared to the prior-year quarter. Once again, this growth was driven by consumer demand and recruiting activities. |
● |
Distributor retention remained steady at 80.3% for the twelve-month period ended March 31, 2020 as compared to all of 2019. Distributor retention is determined by the percentage of active distributors from 2019 that renewed their distributorships in 2020. |
● |
Our average order size in Q1 2020 increased by 3.7% to $398 at suggested retail value compared to the prior-year quarter. In addition, the number of product orders increased by 6.6% in Q1 2020 compared to the prior year quarter. |
International Operations
● |
The average foreign exchange rate for the U.S. dollar for Q1 2020 was stronger against all of the currencies in which we conduct business except for the Philippine peso. Activity in certain markets has been severely impacted by more restrictive COVID-19 guidelines. In particular, activity in Mexico and the Philippines were impacted more severely and earlier than in other markets. |
● |
Australia/New Zealand net sales in Q1 2020 increased by 3.7% in local currency compared to the prior-year quarter as the result of a 1.9% increase in product orders and an increase in new Master Affiliate qualifications. |
● |
Net sales in Canada decreased in Q1 2020 by 19.7% in local currency as the result of a decrease in most forms of distributor activity. |
● |
Net sales in Mexico decreased by 2.3% in local currency in Q1 2020 compared to the prior-year quarter. Distributor activity generally decreased during the quarter as new distributor enrollments and new Master Affiliate qualifications decreased by 58.6% and 62.5%, respectively, in Q1 2020 compared to the prior-year quarter. Product order count decreased by 0.9% in Q1 2020 as well. |
● |
Net sales in Europe increased by 4.2% in local currency in Q1 2020 compared to the prior-year quarter. Similar to the United States, consumer demand was up, particularly in March, with product orders up 2.9%. |
● |
Sales in Asia increased by 7.1% in local currency in Q1 2020 compared to the prior-year quarter. Activity in the region is driven primarily by the Philippines, our largest market in the region. However, the COVID-19 guidelines implemented in the Philippines are extremely restrictive and have severely impaired our sales and activity in the market since mid-March. |
Costs and Expenses
The following table sets forth selected results of our operations expressed as a percentage of net sales for the three-month periods ended March 31, 2020 and 2019. Our results of operations for the periods described below are not necessarily indicative of results of operations for future periods.
Income statement data |
||||||||||||||||
(amounts in thousands) |
Q1 2020 |
Q1 2019 |
||||||||||||||
Amount |
% of net sales |
Amount |
% of net sales |
|||||||||||||
Net sales |
$ | 10,283 | 100.0 |
% |
$ | 9,490 | 100.0 |
% |
||||||||
Costs and expenses: |
||||||||||||||||
Cost of goods sold |
2,655 | 25.8 | 2,434 | 25.6 | ||||||||||||
Distributor royalties and commissions |
3,328 | 32.4 | 3,118 | 32.9 | ||||||||||||
Selling, general and adminstrative |
3,778 | 36.7 | 3,739 | 39.4 | ||||||||||||
Income from operations |
522 | 5.1 | 199 | 2.1 | ||||||||||||
Interest income |
39 | 0.4 | 49 | 0.6 | ||||||||||||
Interest expense |
(6 | ) | (0.1 | ) | (5 | ) | (0.1 | ) | ||||||||
Other expense |
(71 | ) | (0.7 | ) | (6 | ) | (0.1 | ) | ||||||||
Gain on sale of fixed assets |
- | - | 435 | 4.6 | ||||||||||||
Income before income taxes |
484 | 4.7 | 672 | 7.1 | ||||||||||||
Provision (benefit) for income taxes |
(178 | ) | (1.7 | ) | 48 | 0.5 | ||||||||||
Net income |
$ | 662 | 6.4 |
% |
$ | 624 | 6.6 |
% |
||||||||
Earnings per common share-Basic & Diluted |
$ | 0.38 | $ | 0.36 |
Cost of Goods Sold:
● |
The cost of goods sold as a percentage of net sales in Q1 2020 increased by 0.2% compared to the prior-year period. The cost of goods sold as a percentage of net sales in Q1 2020 was negatively impacted by promotions in the United States that reduced our freight income and increases in shipping rates by our primary outbound shipping vendor. |
Distributor Royalties and Commissions:
● |
Distributor royalties and commissions as a percentage of net sales for Q1 2020 decreased by 0.5% of net sales when compared to the prior-year period. This decrease is due to price increases in the United States and other markets in the latter half of 2019 in which distributor commissions were not increased. |
Selling, General and Administrative Expenses:
● |
Selling, general and administrative (“SGA”) expenses increased by $38,000 in Q1 2020 compared to the prior-year period. |
● |
SGA salaries, other staffing expenses, benefits, and incentive compensation increased in the aggregate by $28,000 in Q1 2020, compared to the prior-year period. |
● |
Sales and marketing expenses, excluding compensation, decreased in the aggregate by $2,000 in Q1 2020 compared to the prior-year period. Components of the decrease include: |
o |
$26,000 decrease in promotions expense, distributor conferences and meeting expenses. |
o |
$14,000 decrease in other sales and marketing expenses, including travel and video production expenses. |
o |
Offsetting these decreases is a $38,000 increase in Star Director and other distributor bonuses, credit card fees, and other expenses related to the level of sales. |
● |
Other general and administrative expenses increased by $13,000 in Q1 2020 versus the prior-year period. |
Other Income/Expense:
● |
The other expense in Q1 2020 is primarily the result of foreign currency exchange losses on intercompany debt denominated in U.S. dollars in certain of our subsidiaries. |
● |
Q1 2019 includes $435,000 in income on the sale of our manufacturing equipment as part of the asset sale with Nutracom. |
Income Taxes:
● |
We reported an income tax benefit of $178,000 for Q1 2020. The Coronavirus Aid, Relief, and Economic Security (CARES) Act allowed us to carry our net operating loss that arose in 2018 back five years, generating an income tax benefit of $225,000. The remaining expense is related to income taxes on our earnings in our Philippine entity and minimum U.S. state income tax expense. |
● |
See Note 6 of the Condensed Consolidated Financial Statements for additional detail regarding income taxes. |
Net Income:
● |
We reported net income of $662,000 in Q1 2020 compared to net income of $624,000 in the prior-year quarter as the result of improved sales and gross margin in the quarter, coupled with the income tax benefit recognized under the CARES Act. |
Financial Condition, Liquidity and Capital Resources
During the first three months of 2020, operating activities provided $1.26 million of net cash and $23,000 of net cash was provided by investing activities. This compares to $127,000 of net cash used in operating activities, $11,000 provided by investing activities, and $500,000 provided by financing activities in the same period of 2019. Cash and cash equivalents increased by $1.20 million to $2.83 million as of March 31, 2020 compared to December 31, 2019.
Significant changes in working capital items consisted of an increase in inventory of $190,000, an increase in refundable income taxes of $223,000, an increase in prepaid expenses/other current assets of $365,000, and an increase in accounts payable and accrued expenses of $1.21 million in the first three months of 2020. The increase in inventory is needed to manage the inventory levels in light of the growth in first quarter 2020 net sales, the increase in refundable income taxes is due to the net operating loss carryback that will generate an estimated refund of $225,000, and the increase in prepaid expenses/other current assets primarily represents the annual premium payments made in the first quarter of 2020 on most of the corporate business insurance policies. The increase in accounts payable and accrued expenses is related to higher vendor balances on inventory purchases, financing related to the business insurance renewals, and higher accrued commissions and sales taxes payable as the result of the increase in sales in March 2020 relative to December 2019.
Investing activities during the first three months of 2020 consisted of an investment of $9,000 for capital expenditures, offset by payments received on notes receivable with related parties of $32,000. There were no financing activities during the first three months of 2020.
Stockholders’ equity increased to $11.72 million at March 31, 2020 compared to $11.10 million at December 31, 2019. The increase is due to our net income during the first three months of 2020 of $662,000. Our working capital balance was $2.73 million at March 31, 2020 compared to $1.88 million at December 31, 2019. The current ratio at March 31, 2020 was 1.53 compared to 1.47 at December 31, 2019.
Effective with a renewal agreement as of April 28, 2020, our revolving line of credit with our primary lender was extended for six months with a new maturity date of October 28, 2020 and the borrowing limit continued at $750,000. As renewed, the revolver’s interest rate continued to be based on the 30-day LIBOR plus 3.00%. As of March 31, 2020, we have borrowed $500,000 under our revolving line of credit. Borrowings under the lending agreement continue to be secured by all our tangible and intangible assets and by a mortgage on the real estate of our corporate headquarters.
On May 4, 2020, we executed a promissory note (“SBA Note”) dated April 20, 2020 in the amount of $862,000 with our primary lender under the recently enacted CARES Act Payroll Protection Program (“PPP”). In accordance with the PPP, we will use the loan proceeds of $862,000 primarily for payroll costs. The PPP SBA Note is scheduled to mature April 20, 2022 and has an interest rate of 1.0%. The PPP SBA Note is subject to the terms and conditions applicable to loans administered by the U.S. Small Business Administration under the CARES Act.
We have incurred operating losses, declining net sales, and negative net cash flows over our most recent five years. Our management estimates that these unfavorable trends are more likely than not to continue for the foreseeable future, and as a result, we will require additional financial support to fund our operations and execute our business plan. As of March 31, 2020, we had $2.83 million in cash and cash equivalents which may not be sufficient to fund our planned operations through one year subsequent to the date of the issuance of these condensed financial statements, and accordingly, there is substantial doubt about our ability to continue as a going concern.
In the event that we do not generate sufficient liquidity from operations and should we be unable to obtain sufficient additional capital or borrowings, we may have to engage in any or all of the following activities: (i) seek to monetize our headquarters building via traditional bank lending or a sale and leaseback-type transaction; (ii) monetizing the note receivable from a distributor; (iii) modify our distributor promotions, incentives, and other activities; (iv) cease operations in certain geographic regions, and (v) reduce employee compensation and benefits.
These actions may have a material adverse impact on our ability to achieve certain of our planned objectives. Even if we are able to source additional funding, we may be forced to significantly reduce our operations or shut down our operations if our business operating performance does not improve. These condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event we can no longer continue as a going concern.
Critical Accounting Policies
A summary of our critical accounting policies and estimates is presented in our 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2020. Our critical accounting policies remain unchanged as of March 31, 2020.
Item No. 4 - Controls and Procedures
Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has reviewed and evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2020. Based on such review and evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures were effective as of March 31, 2020, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, (a) is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms and (b) is accumulated and communicated to our management, including the officers, as appropriate to allow timely decisions regarding required disclosure. There were no material changes in our internal control over financial reporting during the first quarter of 2020 that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.
PART II – OTHER INFORMATION
Item No. 6 – Exhibits
Exhibit |
|
Number |
Document |
10.1 |
|
31.1 |
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended (filed herewith). |
31.2 |
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended (filed herewith). |
32 |
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith). |
101 |
Interactive Data Files, including the following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in XBRL: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Net Income and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, (iv) Condensed Consolidated Statements of Stockholders’ Equity, and (v) the Notes to Condensed Consolidated Financial Statements. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
RELIV’ INTERNATIONAL, INC.
By: | /s/ Ryan A. Montgomery | |
Ryan A. Montgomery, Chief Executive Officer | ||
Date: May 15, 2020 | ||
By: | /s/ Steven D. Albright | |
Steven D. Albright, Chief Financial Officer (and accounting officer) | ||
Date: May 15, 2020 |
Exhibit 10.1
Exhibit 31.1
CERTIFICATION
I, Ryan A. Montgomery, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Reliv International, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 15, 2020 |
|
|
|
|
|
|
/s/ Ryan A. Montgomery |
|
|
Ryan A. Montgomery Chief Executive Officer |
|
Exhibit 31.2
CERTIFICATION
I, Steven D. Albright, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Reliv International, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: May 15, 2020 | ||
/s/ Steven D. Albright | ||
Steven D. Albright Chief Financial Officer |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Reliv’ International, Inc. (the “Company”) for the quarterly period ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ryan A. Montgomery, as Chief Executive Officer of the Company, and Steven D. Albright, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Ryan A. Montgomery |
Ryan A. Montgomery
Chief Executive Officer
Date: May 15, 2020
/s/ Steven D. Albright |
Steven D. Albright
Chief Financial Officer
Date: May 15, 2020
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and is not being “filed” as part of the Form 10-Q or as a separate disclosure document for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except to the extent that this Exhibit 32 is expressly and specifically incorporated by reference in any such filing.
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.